Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.98%
#2 Ontology Gas Ontology Gas +137.89%
#3 PulseChain PulseChain +57.64%
#4 ConstitutionDAO ConstitutionDAO +37.37%
#5 Osmosis Osmosis +32.13%
#6 BOOK OF MEME BOOK OF MEME +31.44%
#7 Ontology Ontology +29.58%
#8 Neiro Neiro +29.12%
#9 Collect on Fanable Collect on Fanable +28.57%
#10 Pump.fun Pump.fun +27.30%
Coin of the day
Pleasing Gold Pleasing Gold
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
LianBio LianBio

LianBio

LIAN
Classement en actions #25844
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
Prix de l'action
$0.42275
Dernière synchronisation: 2025-07-14
Capitalisation boursière
$45.81M
Changement (1 jour)
-0.89%
Changement (1 an)
0.00%
Pays
US
Échange LianBio (LIAN)

Catégorie

Healthcare
Revenus pour LianBio (LIAN)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de LianBio, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour LianBio de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US